Skip to main content
NOVT $117.73 -0.14%
NOVT logo
NOVT · Novanta Inc
Track NOVT — free
$117.73 -0.16 (-0.14%) Q1 2026 earnings call transcript
Market Cap
$4.46B
Shares
37.82M
Volume · Nov 19 81.61K Avg daily vol (3M) 441.37K
All webcasts

Earnings call · FY2026 Q3

Novanta Inc (NOVT) Q3 2026 Earnings Call

Concluded Nov 10, 2026
Nov 10, 2026
Period
FY2026 Q3
Runtime
—
Sources
3 artifacts
Revenue $305.01M +23.1% YoY
Diluted EPS $0.05 -83.3% YoY
Gross margin 44.5% -0.3 pp YoY
Net income $2.02M -81.1% YoY
Open full screen Slides 1 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 9, 2026
Novanta reported third-quarter GAAP revenue of $305 million, up 23%, while Adjusted EBITDA rose 38% to $80 million. It expects full-year 2026 GAAP revenue of $1,135 million to $1,140 million and Adjusted EBITDA of $274 million to $277 million.
10-Q report · filed Nov 9, 2026
Novanta’s quarterly revenue rose 23.1% to $305.0 million, but operating income fell 36.3% to $13.9 million, as acquisition-related costs increased. Novanta completed the Riverpoint Medical acquisition for $1,200.6 million upfront, plus a $250.0 million milestone payment.

The audio replay and transcript follow the call.

Forward guidance

13 guided metrics

Management's latest ranges and targets are included below.

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Forward guidance

From the 8-K filed Nov 9, 2026.

Metric Guided
Organic Revenue Growth
full year 2026
7%
Reported revenue growth
full year 2026
16%
Growth in Adjusted EBITDA
full year 2026
at least 24%
Operating cash flow Raised
full year 2026
$200M
Reported revenue growth
2027
at least 15%
GAAP revenue
fourth quarter of 2026
$306M – $312M
Reported revenue growth
fourth quarter of 2026
at least 18%
Adjusted EBITDA
fourth quarter of 2026
$76M – $79M
Adjusted Diluted EPS
fourth quarter of 2026
$0.91 – $0.96
GAAP revenue Raised
full year 2026
$1.14B – $1.14B
Reported growth
full year 2026
16%
Adjusted EBITDA Maintained
full year 2026
$274M – $277M
Adjusted Diluted EPS Lowered
full year 2026
$3.66 – $3.71

Quarter detail

How the reported period landed and where the business moved.

Result vs. guidance

Revenue Above

Revenue · segments

Medical Solutions$159.65M +30.3% YoY
Automation Enabling Technologies$145.35M +16% YoY
Full-screen source Call document